Merck announces data from Phase 3 trials evaluating fixed dose combination of doravirine/islatravir for the treatment of HIV

Back to the "HIV and Co-Infections News" list

Merck announces positive top-line results from pivotal Phase 3 trials evaluating investigational, once-daily oral fixed dose combination of doravirine/islatravir for the treatment of people with HIV-1 infection

  • HIV Treatment
October 26, 2021

Week 48 data met safety and efficacy endpoints in adults with HIV-1 infection currently on antiretroviral therapy

Read the full press release here.

 

Source : Merck

Related HIV and Co-Infections News

See all related HIV and Co-Infections News

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.